NewAmsterdam Pharma Q2 Revenue $2.3M; EPS $(0.41)
Portfolio Pulse from Benzinga Newsdesk
NewAmsterdam Pharma reported Q2 revenue of $2.3 million and an EPS of $(0.41).
August 07, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
NewAmsterdam Pharma reported Q2 revenue of $2.3 million and an EPS of $(0.41). The negative EPS indicates a loss, which may concern investors.
The reported negative EPS of $(0.41) indicates that NewAmsterdam Pharma is currently operating at a loss, which is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100